435 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes (original) (raw)
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
Zhongwu Lai
Oncotarget, 2017
View PDFchevron_right
Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
Giorgio Bogani
Drug Design, Development and Therapy, 2018
View PDFchevron_right
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Zhongwu Lai
British journal of cancer, 2018
View PDFchevron_right
Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization
Zhongwu Lai
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017
View PDFchevron_right
Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12
Angel Denisse Castro
Frontiers in Genetics
View PDFchevron_right
Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
Francesca Carlino
Frontiers in Oncology
View PDFchevron_right
ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status
margarita romeo marin
Gynecologic Oncology, 2021
View PDFchevron_right
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
ana karen
Lancet, 2010
View PDFchevron_right
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
Ayala Hubert
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015
View PDFchevron_right
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
Ronnie Frommer
Oncotarget, 2017
View PDFchevron_right
Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
Ana Frobe
Journal of Oncology
View PDFchevron_right
Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
Aaron Cranston Ph.D.
Clinical Cancer Research, 2011
View PDFchevron_right
Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
Aaron Cranston, S. Shafait
Clinical Cancer Research, 2011
View PDFchevron_right
Ovarian Cancer: BRCA Genetics Reveals Targets for New Therapies
Giuseppe Azzarello
Journal of Genetic Syndromes & Gene Therapy, 2014
View PDFchevron_right
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status
Habib Hamidi
2014
View PDFchevron_right
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Jiuping Ji, Tristan Sissung
JNCI Journal of the National Cancer Institute, 2014
View PDFchevron_right
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Amna Ahmed Ibrahim
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015
View PDFchevron_right
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
James Carmichael
Journal of Clinical Oncology, 2012
View PDFchevron_right
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Paulo Mora
Journal of Clinical Oncology, 2020
View PDFchevron_right
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
Kirsten Timms
2010
View PDFchevron_right
New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
B. Blaumeiser
2016
View PDFchevron_right
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
Jonathan Ledermann
Therapeutic Advances in Medical Oncology, 2019
View PDFchevron_right
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Limor Helpman
The Lancet Oncology, 2017
View PDFchevron_right